Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action
about
Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPDCOPD: maximization of bronchodilation.Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature.Advances in the management of chronic obstructive pulmonary disease.Long-acting inhaled beta 2-agonists for stable COPD.Formoterol: a review of its use in chronic obstructive pulmonary disease.Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.Inhaled therapy for stable chronic obstructive pulmonary disease.Pharmacotherapies for COPD.Budesonide-formoterol (inhalation powder) in the treatment of COPD.Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.[Immediate bronchodilator response to formoterol in poorly reversible chronic obstructive pulmonary disease].Formoterol fumarate inhalation solution (Perforomist) for COPD.Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study.Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
P2860
Q33558856-00DFF681-7E70-44BB-9A46-394A811AECBFQ34436393-ECE7DEB4-18A2-4F67-BC8F-0FF503C686BBQ34834664-D8842947-8DCC-4C9A-8080-693E7BA95F50Q35164693-242CF578-7D8C-422D-A898-3388105915EFQ35201031-708F8173-8996-4B25-8A24-87B3F4AF3AC1Q35627824-1446E12C-6438-409B-AF6E-00829D670DA3Q35841604-A1523296-9CED-4D0E-9BC9-5F4C4F6E2C6BQ36787296-5C457E44-6D8B-479F-9CCD-47C1C243A63AQ36843717-21E1DBA1-DE01-43AE-90D9-9D8F3BD6466BQ37018887-C68C2D61-119F-403F-AAFA-8FE55A39B0F1Q37310689-D168412B-F79D-4CC1-B751-B3C437A3C4FCQ37911291-EA1E8340-A21D-4E16-A23B-9BB19D4CDA66Q38477843-154AE389-4B48-43A2-AEF4-A53DCFA752ACQ39317209-A900FC75-A187-4725-8BD4-84DA6AF4262DQ39317855-002641FA-8C42-46F7-B4E4-75914800BC61Q41846520-9EC7AE75-09B3-4B69-9F9C-A79D826B1E2CQ43732336-DB7371C5-06D0-4F45-BE4A-0E553DC2FA24
P2860
Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action
description
1999 nî lūn-bûn
@nan
1999 թուականին հրատարակուած գիտական յօդուած
@hyw
1999 թվականին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Formoterol and salmeterol in p ...... f onset and duration of action
@ast
Formoterol and salmeterol in p ...... f onset and duration of action
@en
Formoterol and salmeterol in p ...... f onset and duration of action
@nl
type
label
Formoterol and salmeterol in p ...... f onset and duration of action
@ast
Formoterol and salmeterol in p ...... f onset and duration of action
@en
Formoterol and salmeterol in p ...... f onset and duration of action
@nl
prefLabel
Formoterol and salmeterol in p ...... f onset and duration of action
@ast
Formoterol and salmeterol in p ...... f onset and duration of action
@en
Formoterol and salmeterol in p ...... f onset and duration of action
@nl
P2093
P356
P1433
P1476
Formoterol and salmeterol in p ...... f onset and duration of action
@en
P2093
P356
10.1159/000029427
P407
P577
1999-01-01T00:00:00Z